Introduction
Bladdercancer(BCa)isoneofthemostcommoncancers oftheurinarytract,withanestimatedincidencerateofover 380,000newcasesperyearand150,000deathsworldwide (1) .AlthoughtheexactcauseofBCaremainsunknown,afew well-established lifestyle risk factors have been identified, singleC-Asubstitution(C1095A);NAT1*11,ararevariant,manifeststhedeletionofthe9nucleotidesfrom1080to1088 (7) . NAT1*10,with2single-basemutations(T1088AandC1095A), hasbeenreportedtohavehigherenzymaticactivity (5) .
To date, many epidemiological studies have tested the possible association of NAT1*10 allele with the risk of BCa, but the results are still inconsistent or even contradictory. Therefore, we conducted a systemic review and updated meta-analysis of all candidate genetic studies to clarify the realassociationandidentifyanystatisticalevidence.Furthermore,trialsequentialanalysis(TSA)wasforthefirsttimeused toclarifywhethertheevidencefortheresultswassufficient.
Materials and methods

Literature search strategy
We performed an exhaustive search of studies that examined the association of NAT1 polymorphisms and susceptibility to BCa. Data were collected from the electronic databasesPubMed,EmbaseandWebofScienceavailableup toJuly1,2016,usingthefollowingkeywords:"NAT1"or"Nacetyltransferase 1"; "variants" or "polymorphism"; "single nucleotide polymorphism," and "bladder cancer," "bladder neoplasm"or"bladdertumor"separatelyorcombined.The researchwasrestrictedtohumansubjectsonly.Allreferences citedintheretrievedarticleswerereviewedtoidentifyother relevantpublications.Reviewarticleswerealsoinspectedto findadditionaleligiblestudies.Also,weonlyconsideredstudiespublishedinEnglish.
Inclusion and exclusion criteria
Studies using an analytic design (case-control, nested case-control or cohort) and employing validated genotype methodstoexaminethefrequencyofNAT1amongBCacases andcontrolswereeligibleforinclusion.Studiesshouldinclude sufficientgenotypedataforanalysis.Casereports, letters,reviewsandeditorialarticleswereexcluded.Additionally,when duplicationsorthesamepatientpopulationsusedinseveral publicationsexisted,onlythemostrecentorcompletestudy wasincludedinthismeta-analysis.
Data extraction
Twoinvestigators(Z.X.andX.L.)independentlyextracted the data with a standard protocol, and the result was reviewed by a third investigator (B. Y.). We extracted the followinginformation:firstauthor'ssurname,yearofpublication,countryoforigin,ethnicityofsubjects,sexofsubjects, sourceofcontrols,genotypemethodandsourceofcontrols, andsubdividedthesubjectsinto2groups(without*10and with*10)bynumbersofNAT1*10allelesincontrolandcase groups,respectively.
Statistical analysis
In this meta-analysis, the following variations for NAT1 polymorphism were evaluated: without NAT1*10 and with NAT1*10.Allassociationswerepresentedasthepooledodds ratios (ORs) with the corresponding 95% confidence intervals(CIs).Afterthat,subgroupanalyseswereconductedon the basis of ethnicity, sex, source of controls and detecting methods. Between-study heterogeneity was tested using thechi-square-basedQ-test.Inaddition,weseparatelyused random-effectsandfixed-effectsmodelstoanalyzethedata forthestabilityoftheresults (8, 9) .Sensitivityanalysiswas conducted by excluding a single study 1 by 1, to check for stability and reliability on the pooled ORs by repeating the meta-analysis.Inaddition,publicationbiaswasinvestigated by Begg's funnel plot, and the funnel plot was assessed by Egger'slinearregressiontest (10) .Statisticalsignificancewas considered when the p value of Egger's test was <0.05. All statistical analyses were carried out using STATA software (version12.0;StataCorpLP,CollegeStation,TX,USA).Toensure the reliability and accuracy of the results, 2 reviewers (Z.X.andX.L.)inputtedthedatainthestatisticalsoftware programsindependentlyandobtainedthesameresults.The studygrouphassubstantialexperienceinconductingoncologicalresearchandhaspublishedsimilarstudieselsewhere.
Trial sequential analysis
Theoutcomesofameta-analysismightresultintypeIerrors duetorepetitivetestingofaccumulateddataandareproneto systematicorrandomerrorswithsparsedatacollected (11, 12) . TSAwasintroducedtoestimatetherequiredinformationsize byadjustingthethresholdforsignificancelevelwithdispersed data and to confirm greater statistical reliability of the data thanwithatraditionalmeta-analysis (11, (13) (14) (15) .Inthecurrent meta-analysis,TSAwasperformedbymaintaininga95%con-fidenceinterval,a20%relativeriskreduction,anoveralltypeI errorof5%andastatisticaltestpowerof80%,fromwhichthe requiredinformationsizewascalculatedandthetrialsequentialmonitoringboundarieswereconstructed.Ifthecumulative Z-curve(theblueline)crossesthetrialsequentialmonitoring boundary(slopingredline)orexceedstherequiredinformation size(verticalredline),asignificantresulthasbeenreached,and no further studies are needed. Otherwise, if the cumulative Z-curvedoesnotcrosstheboundaryortheinformationsizerequiredhasnotbeenreached,weneedadditionalclinicaltrials toreachtheadequateinformationsizerequiredforobtaining sufficientevidence (11, 12, (16) (17) (18) .TheTSAsoftware(TSA,version0.9,2011;CopenhagenTrialUnit,Copenhagen, Denmark) wasusedinthisstudy.
Results
Study characteristics
Based on the inclusion and exclusion criteria, 17 studies wereevaluableinthecurrentmeta-analysis (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) .Thefirst onewaspublishedin1997 (22) andthelastin2012 (32) .The detailedcharacteristicsoftheselectedstudiesarepresentedin TableI.Theprocessofliteraturesearchandexclusionisshown inFigure1.Atotalof17studieswereinvestigatedwith4,322 BCa cases and 4,944 controls. All studies were case-control studiesthatevaluatedtheassociationbetweenNAT1polymor-phism and BCa susceptibility. Among these previous studies, 11 studies were conducted in white populations, 1 was in a Any NAT1*10 = rapid acetylation; HB = hospital-based controls; Non-NAT1*10 = slow acetylation; PB = population-based controls; PCR-RFLP = polymerase chain reaction-restriction fragment length polymorphism; SOC = source of controls.
Fig. 1 -Flowdiagramofliteraturesearch andselectionprocess.
N-Acetyltransferase 1 polymorphism and bladder cancer e300 All data were calculated using slow acetylation vs. rapid acetylation. HB = hospital-based; PB = population-based; PCR-RFLP = polymerase chain reaction-restriction fragment length polymorphism. * p value of Q-test for heterogeneity. non-Asianpopulation,2wereinmixedracepopulationsand theremaining3studieswereconductedinAsianpopulations. Inaddition,restrictionfragmentlengthpolymorphism(RFLP) analysiswasreportedin12publications,andTaqMananalysis wasperformedintheremaining5studies.
Quantitative synthesis results
Asummaryofthemeta-analysisfindingsoftheassociationbetweenNAT1*10alleleandtheriskofBCaislistedin
TableII.Theresultsofthemeta-analysisshowedthatthere wasnoassociationbetweenNAT1*10alleleandBCariskin the comparisons of individuals without NAT1*10 and with NAT1*10,intherandom-effectsmodel(OR=0.96,95%CI, 0.84-1.10)orinthefixed-effectsmodel(OR=0.95,95%CI, 0.87-1.03) (Fig.2) .
Forthestratifiedanalysesbyethnicity,sex,sourceofcontrolanddetectingmethods,theresultsareshowninFigure3. TherewerenoobviousassociationsbetweenNAT1*10allele andtheriskofBCainanyothersubgroupanalysis. 
Sensitivity analysis
Sensitivityanalysiswasperformedbyomitting1included studyatatime,todistinguishtheinfluenceofeachindividual study on the pooled ORs, repeating the meta-analysis. The sensitivityanalysisoftheassociationbetweentheNAT1*10 alleleandtheriskofBCaisshowninSupplementaryFigure1 (availableonlineatwww.biological-markers.com-Sensitivity analysis under the random model), demonstrating that the recalculated ORs were not substantially influenced. Therefore, the sensitivity analysis indicated that our results were robustandstable.
Publication bias
TheBegg'sfunnelplotandEgger'stestwereperformed toassessthepublicationbiasoftheliteratureinthismetaanalysis. The shape of the funnel plot did not reveal any evidenceofobviousasymmetry,andtheoutcomeofEgger's testprovidedstatisticalevidenceforthesymmetryofBegg's funnel plot (p = 0.487). Thus, there was no obvious publication bias of the literature included in this meta-analysis (seeSupplementary Figure2,availableonlineatwww.biological-markers.com-Begg'sfunnelplotofpublicationbiastest intherandommodel). 
TSA results
Inourpresentstudy,Figure4showsthatnotonlydidthe cumulativeZ-curvenotcrossthetrialsequentialmonitoring boundary, but also the total number of cases and controls werenotmorethantherequiredinformationsize,showing theresultstoneedtobefurtherverified.
Discussion
Thissystematicreviewprovidesthemostrecentandcomprehensive assessment of the NAT1*10 allele in BCa. Many previousstudiesinthepast2decadeshaveinvestigatedsuch an association, but the results have remained inconclusive. Among these, Carreón et al (29) found individuals carrying NAT1wt/*10andNAT1*10/*10showedahigherrelativerisk of BCa. However, Gu et al (34) found there was no significantassociationbetweenriskofBCaandtheNAT1*10allele. Evidencesuggestedthatthepolymorphismsinactivatingand detoxifyingenzymesmightinteracttoaffectthelevelofDNA damage sustained by a specific tissue and ultimately influence disease risk (36) . Therefore, the imbalances between activationanddetoxificationprocessesmightresultinanincrease in the susceptibility of BCa due to the accumulation ofcarcinogenmetabolites,suchasfromcigarettesmokingor exposuretocarcinogenicamines.
Asastatisticalanalysistool,meta-analyseshaveagreater powerthanasinglestudyespeciallyinanalyzingunexplained studiesandcanprovidemoresubstantialresults.Inthepresent study, there was a much stronger advantage toward showing any association between the NAT1*10 allele and susceptibilitytoBCa:forexample,thesamplesizeinthismeta-analysiswaslargerthanthatofanyindividualstudy,which mightmakeourresultsmorereliableandrobust.Thecurrent meta-analysis suggested that the NAT1*10 allele could not influencetheriskofBCa. NAT1*10 was suspected to lead to higher enzymatic activitythanNAT1*4inthebladdermucosa(5).However, basedonthe17studiesinourmeta-analysis,therewasno associationbetweentheNAT1*10alleleandBCarisk.We furtherconductedasubgroupanalysisandfoundnoobvious association between the NAT1*10 allele and the risk ofBCa.
Inaddition,becauseofthelimiteddata,itcouldbethat thismeta-analysiswasunderpoweredtoexploreanyrealassociation.Therefore,TSAwasadoptedinthismeta-analysis, forthefirsttimetoreducetheriskoftypeIerrorandverify whethertheevidenceofourresultswassufficient.
In conclusion, we need a better method to analyze and understandtheassociationbetweentheNAT1*10alleleand theriskofBCa.Therefore,toguaranteethereliabilityofour meta-analysis,moreresearchshouldfocusontheinfluence ofdifferentfactorsinthefuture.
TSAisapowerfulandusefulapproachtowardthegoalof summarizing evidence and determining the required informationsizeinmeta-analyses (12, 37) .Toreducetheriskof atypeIerrorandestimatewhetherfurthertrialsareneeded,TSAisintroducedtocalculatetherequiredinformation sizeforthemeta-analysiswiththeadaptationofmonitoring boundaries (38) . However, the meta-analyses not reaching the required sample size are analyzed with trial sequential monitoringboundaries,whichissimilartointerimmonitoring boundaries in a single trial (12, 17, 18, 39) . Compared withthetraditionalmeta-analysistechniques,TSAshowsthe potentialtobemorereliable.Ifthesufficientinformationsize isnotreached,falsepositiveresultsareeliminatedearlydue torandomerrorsandrepeatedsignificancetestinginmetaanalyses (11, 12, 39) .Furthermore,whenreliableevidence is obtained, as demonstrated by TSA, researchers can stop implementationoffurtherstudies.Otherwise,itisnecessary toreestimatetheadditionalnumberofpatientsrequiredto obtainreliableresultsinthemeta-analyses,therebyguiding researchers in subsequent studies (40, 41) . In the present meta-analysis, the number of cases and controls included were not more than the required information size, which meantthatourresultsmightnotbefirm evidenceofeffect.
Notably, there were several limitations to this metaanalysis. Firstly, the controls were not uniformly defined, because some controls were hospital-based. Hence, nondifferential misclassification bias is possible. Secondly, all publishedstudieswerewritteninEnglish.Itispossiblethatsome related,publishedorunpublishedstudiesthatmightmeetthe inclusioncriteriaweremissed.Thus,someinevitablepublicationbiasmightexistintheresultsofthemeta-analyses,though thefunnelplotsaswellasEgger'slinearregressiontestsindicatednoremarkablepublicationbiases.Whatismore,inthe subgroupanalysisbyethnicity,thepopulationofwhitescame from 3 continents -North America, Europe and the Middle East -which might cause a selection bias. Furthermore, we excludedanyinteractionsamonggenesandenvironmentsuch asNAT2,theinfluenceofsmokingandexposuretobenzidine oranyothercarcinogens,andlackingtheoriginaldataofthe studies included limited our further evaluation of potential interactions. Additionally, additional studies about exploring theriskeffectsofthispolymorphismwith susceptibilitytoBCa needtobefurthervalidatedinsubsequentstudies.
Conclusions
In summary, despite its limitations, the results of the presentmeta-analysissuggestedthattherewasnoassociationbetweentheNAT1polymorphismandtheriskofBCain the comparisons of individuals without NAT1*10 and with NAT1*10. Moreover, in the subgroup analysis, there were no obvious associations between the NAT1*10 allele and susceptibility to BCa. More importantly, our findings need tobefurthervalidatedregardingwhetherbeingwithoutthe NAT1*10allelecouldinthefuturebeshowntobeapotential etiologyandmarkerfortheriskofBCa.
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